Researchers Say Not All A-Fib Patients Need Anticoagulation

Share this content:
Researchers Say Not All A-Fib Patients Need Anticoagulation
Researchers Say Not All A-Fib Patients Need Anticoagulation

TUESDAY, Oct. 18, 2016 (HealthDay News) -- Some patients with atrial fibrillation who have implanted pacemakers or defibrillators may not always need anticoagulation, according to a study published online Oct. 17 in Circulation.

Steven Swiryn, M.D., a clinical professor of cardiology at the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues looked at 37,531 electrograms from 5,379 patients over two years. All the participants took part in the RATE Registry (Registry of Atrial Tachycardia and Atrial Fibrillation Episodes), an ongoing study that follows patients with pacemakers or defibrillators.

The researchers found that patients who had only short bouts of atrial fibrillation -- estimated at 20 seconds or less -- were at no more risk for stroke or other cardiovascular complications than patients without atrial fibrillation.

"We knew that people with atrial fibrillation are at higher risk of stroke, but the next question was, how much atrial fibrillation?" Swiryn said in a news release from the American Heart Association. "Other studies have shown that prolonged episodes of atrial fibrillation pose a risk, but what about short ones? The answer until this study was 'no one knows.' Now we have good solid data that if all you have is short episodes of atrial fibrillation, the risk is so low that it doesn't warrant anticoagulants."

Several authors disclosed financial ties to pharmaceutical and medical device companies, including St. Jude Medical, which funded the RATE Registry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »